Physician profile
Liliane Lebas
NPI 1922178334
$1,668.95
in general payments reported to CMS, 2019-2025
11 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $38.87 · 2021: $277 · 2022: $50.56 · 2023: $273 · 2024: $504 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.38 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $383.07 | 2023-2025 | Uzedy, Austedo |
| Lundbeck LLC | $360.46 | 2019-2025 | Abilify Maintena |
| Abbvie INC. | $259.04 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.59 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $108.59 | 2019-2023 | Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $107.08 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $97.97 | 2019-2022 | |
| Allergan, INC. | $54.60 | 2019-2020 | |
| Indivior INC. | $47.76 | 2019-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $44.03 | 2019 | |
| Alkermes, INC. | $24.76 | 2024 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liliane Lebas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.